Catalyst Wire Dossier Catalyst Wire Dossier

XPOVIO

selinexor · Karyopharm Therapeutics
Drug timelines are a Plus or Pro feature.

27 regulatory and trial events tracked for XPOVIO, covering 2019-07-03 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma [Phase 2]

See pricing